Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Kreitman Website

Robert J. Kreitman, M.D.

Selected Publications

1)  Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I.
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
N. Engl. J. Med. 345: 241-7, 2001.
2)  Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I.
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
J. Clin. Oncol. 27: 2983-90, 2009.
3)  Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ.
VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
Blood. 114: 4687-95, 2009.
4)  Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I.
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia.
J. Clin. Oncol. 30: 1822-8, 2012.
5)  Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ.
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.
Blood. 119: 3330-2, 2012.
6)  Arons E, Adams S, Venzon DJ, Pastan I, Kreitman RJ.
Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.
Br. J. Haematol. [Epub ahead of print], 2014.
7)  Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS.
High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.
Nat. Genet. 46: 8-10, 2014.
8)  Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I.
Immunotoxins for leukemia.
Blood. 123: 2470-7, 2014.
9)  Mazor R, Eberle JA, Hu X, Vassall AN, Onda M, Beers R, Lee EC, Kreitman RJ, Lee B, Baker D, King C, Hassan R, Benhar I, Pastan I.
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.
Proc. Natl. Acad. Sci. U.S.A. 111: 8571-6, 2014.
10)  Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA.
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
Br. J. Haematol. [Epub ahead of print], 2014.
11)  Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ.
Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.
Clin. Cancer Res. 19: 6313-21, 2013.
12)  Kreitman RJ, Wilson W, Calvo KR, Arons E, Roth L, Sapolsky J, Zhou H, Raffeld M, Stetler-Stevenson M.
Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
Clin. Cancer Res. 19: 6873-81, 2013.
13)  Shao H, Calvo KR, Grönborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM.
Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.
Leuk. Res. 37: 401-9, 2013.
14)  Kreitman RJ.
Hairy cell leukemia-new genes, new targets.
Curr Hematol Malig Rep. 8: 184-95, 2013.
15)  Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 5: 208ra147, 2013.
16)  Tembhare PR, Marti G, Wiestner A, Degheidy H, Farooqui M, Kreitman RJ, Jasper GA, Yuan CM, Liewehr D, Venzon D, Stetler-Stevenson M.
Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.
Am. J. Clin. Pathol. 140: 813-8, 2013.
17)  Kreitman RJ.
Immunoconjugates and new molecular targets in hairy cell leukemia.
Hematology Am Soc Hematol Educ Program. 2012: 660-6, 2012.
18)  Simone CB, Morris JC, Stewart DM, Urquhart NE, Janik JE, Kreitman RJ, Lita E, Conlon K, Wharfe G, Waldmann TA, Kaushal A.
Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma.
Blood. 120: 1816-9, 2012.
19)  Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, Pastan I.
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.
Proc. Natl. Acad. Sci. U.S.A. 109: 11782-7, 2012.
20)  Singh R, Zhang Y, Pastan I, Kreitman RJ.
Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.
Clin. Cancer Res. 18: 152-60, 2012.
21)  Biberacher V, Decker T, Oelsner M, Wagner M, Bogner C, Schmidt B, Kreitman RJ, Peschel C, Pastan I, Meyer Zum Büschenfelde C, Ringshausen I.
The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
Haematologica. 97: 771-9, 2012.
22)  Kreitman RJ, Pastan I.
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Clin. Cancer Res. 17: 6398-405, 2011.
23)  Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M.
Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders.
Am. J. Clin. Pathol. 136: 625-30, 2011.
24)  Fitzgerald DJ, Moskatel E, Ben-Josef G, Traini R, Tendler T, Sharma A, Antignani A, Mussai F, Wayne A, Kreitman RJ, Pastan I.
Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
Leuk. Lymphoma. 52 Suppl 2: 79-81, 2011.
25)  Arons E, Roth L, Sapolsky J, Suntum T, Stetler-Stevenson M, Kreitman RJ.
Evidence of canonical somatic hypermutation in hairy cell leukemia.
Blood. 117: 4844-51, 2011.
26)  Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R.
Immunotoxins with decreased immunogenicity and improved activity.
Leuk. Lymphoma. 52 Suppl 2: 87-90, 2011.
27)  Arons E, Kreitman RJ.
Molecular variant of hairy cell leukemia with poor prognosis.
Leuk. Lymphoma. 52 Suppl 2: 99-102, 2011.
28)  Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, Pastan I.
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
Proc. Natl. Acad. Sci. U.S.A. 108: 5742-7, 2011.
29)  Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I.
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Leuk. Lymphoma. 52 Suppl 2: 82-6, 2011.
30)  Traini R, Kreitman RJ.
Renal excretion of recombinant immunotoxins containing pseudomonas exotoxin.
Bioconjug. Chem. 22: 736-40, 2011.
31)  Kreitman RJ, Arons E, Stetler-Stevenson M, Miller KB.
Response of hairy cell leukemia to bendamustine.
Leuk. Lymphoma. 52: 1153-6, 2011.
32)  Kreitman RJ.
Synergistic targeting of leukemia with leukotoxin and chemotherapy.
Leuk Res. 35: 1438-9, 2011.
33)  Kawa S, Onda M, Ho M, Kreitman RJ, Bera TK, Pastan I.
The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.
MAbs. 3: 479-86, 2011.
34)  Blake-Haskins JA, Lechleider RJ, Kreitman RJ.
Thrombotic Microangiopathy with Targeted Cancer Agents.
Clin Cancer Res. 17: 5858-66, 2011.
35)  Kreitman RJ, Polliack A, Grever M.
Treatment of hairy cell leukemia in its second half-century: an international conference on hairy cell leukemia at the National Institutes of Health, April 26-27, 2010, Bethesda, MD.
Leuk. Lymphoma. 52 Suppl 2: 1-2, 2011.
36)  FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I.
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
Cancer Res. 71: 6300-9, 2011.
37)  Jasper GA, Arun I, Venzon D, Kreitman RJ, Wayne AS, Yuan CM, Marti GE, Stetler-Stevenson M.
Variables affecting the quantitation of CD22 in neoplastic B cells.
Cytometry B Clin Cytom. 80: 83-90, 2011.
38)  Wang L, Abbasi F, Jasper GA, Kreitman RJ, Liewehr DJ, Marti GE, Stetler-Stevenson M.
Variables in the quantification of CD4 in normals and hairy cell leukemia patients.
Cytometry B Clin Cytom. 80: 51-6, 2011.
39)  Kreitman RJ, FitzGerald DD.
Pandalai S, eds.
Recombinant immunotoxins for the treatment of cancer. In: Targeted Drug Delivery in Cancer Therapeutics.
Kerala, India: Research Signpost, T.C; 2010. p. 127-157 [Book Chapter]
40)  Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, Fitzgerald DJ, Pastan I.
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Clin. Cancer Res. 16: 1894-903, 2010.
41)  Bogner C, Dechow T, Ringshausen I, Wagner M, Oelsner M, Lutzny G, Licht T, Peschel C, Pastan I, Kreitman RJ, Decker T.
Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression.
Br. J. Haematol. 148: 99-109, 2010.
42)  Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, Pastan I.
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
Blood. 113: 3792-800, 2009.
43)  Kreitman RJ, Fitzgerald DJ, Pastan I.
Approach to the patient after relapse of hairy cell leukemia.
Leuk. Lymphoma. 50 Suppl 1: 32-7, 2009.
44)  Alderson RF, Kreitman RJ, Chen T, Yeung P, Herbst R, Fox JA, Pastan I.
CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.
Clin. Cancer Res. 15: 832-9, 2009.
45)  Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I.
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
Clin. Cancer Res. 15: 5274-9, 2009.
46)  Kreitman RJ.
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 23: 1-13, 2009.
47)  Kreitman RJ.
Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
Curr. Pharm. Des. 15: 2652-64, 2009.
48)  Ahmad E, Steinberg SM, Goldin L, Hess CJ, Caporaso N, Kreitman RJ, Wiestner A, Wilson W, White T, Marti G, Stetler-Stevenson M.
Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia.
Cytometry B Clin Cytom. 74: 221-6, 2008.
49)  Arons E, Suntum T, Margulies I, Yuan C, Stetler-Stevenson M, Kreitman RJ.
PRAME expression in hairy cell leukemia.
Leuk. Res. 32: 1400-6, 2008.
50)  Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ.
Soluble CD22 as a tumor marker for hairy cell leukemia.
Blood. 2008.
51)  Powell DJ, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, White DE, Mavroukakis S, Kreitman RJ, Rosenberg SA, Pastan I.
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
J. Immunol. 179: 4919-28, 2007.
52)  Filpula D.
Antibody engineering and modification technologies.
Biomol. Eng. 24: 201-15, 2007.
53)  Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I.
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.
Leukemia. 21: 169-74, 2007.
54)  Arons E, Suntum T, Sunshine J, Stetler-Stevenson M, Kreitman RJ.
Immunoglobulin light chain repertoire in hairy cell leukemia.
Leuk. Res. 31: 1231-6, 2007.
55)  Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ.
Immunotoxin treatment of cancer.
Annu. Rev. Med. 58: 221-37, 2007.
56)  Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I.
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
Clin. Cancer Res. 13: 5144-9, 2007.
57)  Filpula D, Yang K, Basu A, Hassan R, Xiang L, Zhang Z, Wang M, Wang Q, Ho M, Beers R, Zhao H, Peng P, Zhou J, Li X, Petti G, Janjua A, Liu J, Wu D, Yu D, Zhang Z, Longley C, FitzGerald D, Kreitman RJ, Pastan I.
Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
Bioconjug. Chem. 18: 773-84, 2007.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/20/2014.